Meet the Team

Meet the Team

Parent Board

Bonnie Dwyer, M.D., lives in the San Francisco Bay Area and is the mother of Alexandra, a 16-year-old with a CAMK2B mutation, and Zachary, a neurotypical 9-year-old. One of the founding members of CAMK2 Therapeutics Network and a CAMK2 activist, Bonnie is a maternal fetal medicine physician board certified in internal medicine, OB/GYN, and maternal fetal medicine. Her husband, Ian Carroll, M.D., is a pillar of support to Alexandra, who would not be as happy and healthy as she is today without his infinite love, constant attention to her well-being, and daily patience and humor.

Neville Ross lives in Dublin, Ireland, with his wife, Christine, and their children Caoimhe, 15, who has a mutation on the CAMK2B gene, and 17-year-old Shannon, who is neurotypical. Christine is Caoimhe’s full-time caregiver. Nev, a founding member of CAMK2 Therapeutics Network, had an essential role in building the relationship with the ENCORE CAMK2 Center of Expertise in Rotterdam and organized the first global CAMK2 gathering in the Netherlands in 2019. A professional software engineer, he is vice president of engineering for a large multinational corporation.

Matt Gibbs lives north of Boston, Mass., with his wife, Pam, and their children Lana, 10, who has a mutation on the CAMK2B gene, and 12-year-old Tucker, who is neurotypical. Lana’s CAMK2B variant was identified in 2016 using whole-exome sequencing, one of the first times worldwide that the technology was used to identify the disorder. Pam and Matt have been advocating for Lana since that day. Matt, a founding member of CAMK2 Therapeutics Network, focuses his efforts on building connections with parents, family members, researchers and clinicians. He is a sales professional enabling technology solutions for corporations and nonprofits throughout the United States.

Inês Bastos lives in Setúbal, Portugal, with her husband, Hugo, and their children, Teresa, a 7-year-old girl with a CAMK2A mutation, and Afonso, a neurotypical 5-year-old boy. Inês is a social worker who believes in people’s ability to positively influence the goal of leaving no one behind. A specialist in social innovation, diversity and inclusion and development studies, Inês also is an activist by heart and soul. She advocates for CAMK2 Therapeutics Network’s mission, treasuring her role as part of the parent team. She invites other families to share their stories and photos in her newsletter.

Gillian McKenzie lives in Ayr, Scotland, with her husband, Scott, and their children, 5-year-old Alex and 10-year-old Daniel, who has a CAMK2A gene mutation. In addition to caring for Daniel full time, Gillian also is an autism outreach teacher, helping families, teachers and therapists to work cooperatively to support autistic children in mainstream education.

Scientific Advisory Board

Dr. Howard Schulman, Ph.D., the “Father of CAMKII,” co-discovered the kinase activity now referred to as CAMKII with Nobel Laureate Paul Greegard. A major contributor and thought leader in understanding how CAMKII transmits information from neurotransmitters and calcium-linked hormones, and the role of cytokines in brain, heart and endocrine systems, he was a key contributor to identifying how various mutations alter CAMKII’s activity. At Stanford University School of Medicine he was professor of Neurobiology and of Pharmacology, and chair of the Department of Neurobiology. He also co-founded and was CEO of a biotechnology company developing inhibitors of CaMKII, and served as a reviewer of grant applications for NIH, Michael J Fox Foundation and several international granting agencies.

Dr. Jan Brunstrom, M.D., a pediatric neurologist, owns and directs 1 CP Place PLLC, a Plano, Texas, clinic for children with cerebral palsy and similar motor disorders. A wife and mother who herself has cerebral palsy, she is a steering committee member of the international Multidisciplinary Prevention and Cure Team for Cerebral Palsy and a member of the Scientific Advisory Committee for the Cerebral Palsy Foundation in New York. Before moving to Texas, she was founding director of the Pediatric Neurology Cerebral Palsy Center at Washington University School of Medicine and medical director of the Carol and Paul Hatfield Sports and Rehabilitation Program at St. Louis Children’s Hospital. A graduate of the Medical College of Virginia at Virginia Commonwealth University in Richmond, Virginia, she completed her pediatric neurology training at St. Louis Children’s Hospital.

For appointments, contact (469) 331-0030

Dr. Elliott Sherr, M.D., a professor in neurology and pediatrics at the Weill Institute of Neurosciences and the Institute of Human Genetics at the University of California San Francisco, is founder and director of UCSF’s Brain Development Research Program, which studies the genetics and biology of autism and epilepsy (brain.ucsf.edu). He co-directs the neurometabolic program and clinic at UCSF, and is an active attending physician in the child neurology division. After completing undergraduate degrees in philosophy and biology at Stanford University, he obtained his M.D. and Ph.D. at Columbia University in New York and completed his clinical training in pediatrics and neurology at UCSF.

For appointments, contact (415) 353-2525. Let scheduler know the appointment specifically needs to be with Dr. Sherr

Dr. Kiki Chang, M.D., is a child, adolescent and adult psychiatrist in private practice in Palo Alto. Formerly on the faculty of the Stanford University School of Medicine, Division of Child Psychiatry, he directed the Pediatric Bipolar Disorders Clinic and Research Program, specializing in pediatric psychopharmacology and treatment of depression and bipolar disorder. His research includes brain imaging, genetics, and medication and psychotherapy trials designed to identify those at highest risk for bipolar disorder and methods to intervene to prevent its onset. Dr. Chang also co-founded the Stanford Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) Clinic and Research Program at the Lucille Packard Children’s Hospital at Stanford. A graduate of Princeton University, he received his M.D. from the Tufts University School of Medicine, completed his general psychiatry residency at the University of Cincinnati and his child psychiatry fellowship and a postdoctoral research fellowship at Stanford University.

For appointments, contact (650) 503-4217. http://kikichangmd.com

Scientific Partners

Dr. Danielle Veenma,  M.D., Ph.D. 

Dr. Geeske van Woerden, Ph.D.

ENCORE CAMK2 Center of Expertise, Erasmus Medical Center, Rotterdam, Netherlands, is multidisciplinary program composed of researchers and medical specialists working to directly translate information learned in the laboratory into therapies for affected individuals. The Center has developed a CAMK2 Care pathway designed to support parents and help practitioners deliver the highest-quality medical treatment of the disorder.

Founded in 2010, the ENCORE program is world-renowned for its work with Angelman Syndrome, has published one of the largest studies of the syndrome in children and adults and has begun clinical trials for treatment. The ENCORE CAMK2 Center will use lessons learned from the Angelman Syndrome branch and apply them directly to CAMK2 gene-related illness.

Dr. Danielle Veenma, M.D., Ph.D., a genetics and complex care pediatrician, and Dr. Geeske van Woerden, Ph.D., lab head of the Center’s Department of Neuroscience, lead ENCORE’s CAMK2 program. They have close ties to our Network, and together we have sponsored three annual international meetings for scientists and families.

Dr. Veenma spearheads the CAMK2 Natural History Study, a physician-powered registry that collects genotype and phenotype information. She also is developing a biobank. Dr. van Woerden is developing patient-specific assays, back-engineered from stem cells in a patient’s blood, to study how that patient’s mutation alters CAMK2 activity and to test the effectiveness of potential drugs.

In addition to Drs. Veenma and van Woerden, the Encore CAMK2 clinical team includes Dr. MC de Wit, a pediatric neurologist, and Dr. L ten Hoopen, a child and adolescent psychiatrist.

 


Dr. Margaret Stratton, Ph.D.

Stratton Lab Dr. Margaret Stratton, Ph.D., University of Massachusetts Amherst Department of Biochemistry and Molecular Biology, heads the lab whose goal is to understand CAMKII regulation, and other proteins, at the molecular level. Lab members use this molecular information,  protein structure and regulation, for example, to study the effect of CAMKII activity on the full organism, mouse or human.